Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amag Pharmaceuticals (NQ: AMAG )

13.75 USD UNCHANGED
Last Price Updated: 4:06 PM EST, Nov 13, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amag Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)
Feraheme is Now a Treatment Option for All Eligible Adult Patients with Iron Deficiency Anemia 
From GlobeNewswire News Releases
Pre-Market Technical Scan on Diagnostic Substances Equities -- Advanced Accelerator Applications, AMAG Pharma, DBV Technologies, and IDEXX Labs
From PR Newswire
AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including preliminary unaudited fourth quarter and full year 2017 financial results and 2018 financial guidance. The company... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Awards $300,000 in Grants to Further Research in Preterm Birth and Neonatal Health
As part of the company’s ongoing support of maternal and neonatal health, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has awarded four grants totaling $300,000 to independent... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday,... 
From GlobeNewswire News Releases
New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"
Patent designed to protect the subcutaneous administration of Makena(R) (hydroxyprogesterone caproate injection) 
From GlobeNewswire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within Xilinx, J.B. Hunt Transport Services, Southern, FirstEnergy, AMAG Pharmaceuticals, and Galectin Therapeutics — New Research Emphasiz
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Xilinx, Inc.... 
From GlobeNewswire News Releases
Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea
Palatin to Receive $500,000 Upfront 
From PR Newswire
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 2:40 p.m. GMT (9:40 a.m.... 
From GlobeNewswire News Releases
AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy
More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients 
From GlobeNewswire News Releases
Hypophosphatemia Data From AMAG Phase 3 Trial Presented at the American Society of Nephrology
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced data related to the occurrence of hypophosphatemia following intravenous (IV) iron treatment at a podium presentation at the 2017 American... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the quarter ended September 30, 2017 and updated its full year 2017 financial guidance. 
From GlobeNewswire News Releases
Technical Insights on Diagnostic Substances Stocks -- Atossa Genetics, AMAG Pharma, IDEXX Laboratories, and Quidel
From PR Newswire
AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 2, 2017 at 8:00 a.m. ET
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its third quarter 2017 financial results will be released on Thursday, November 2, 2017 before the U.S. financial markets open. Management... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Tracy Palmer Berns as chief compliance officer effective immediately. She will report to Joseph Vittiglio, general counsel... 
From GlobeNewswire News Releases
Today's Research Report Coverage on Healthcare Stocks -- AMAG Pharma, IDEXX Laboratories, Palatin Technologies, and Bio-Path
From PR Newswire
AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Laura Williams, M.D., M.P.H., as senior vice president of clinical development effective immediately. She will report to... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: 
From GlobeNewswire News Releases
AMAG Announces U.S. FDA Filing Acceptance and Six-Month Review of Feraheme® (ferumoxytol) for the Treatment of All Adult Patients With Iron Deficiency Anemia
Prescription Drug User Fee Act (PDUFA) Target Action Date of February 2, 2018 Established 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Oscar Sanchez as vice president of quality effective immediately. He will report to Joseph Vittiglio, general counsel and... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the quarter ended June 30, 2017. Total GAAP revenue for the second quarter of 2017 increased to a... 
From GlobeNewswire News Releases
AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of All Adult Patients With Iron Deficiency Anemia
Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has completed the submission to the U.S. Food and Drug Administration (FDA) to broaden the existing label for Feraheme® (ferumoxytol) to... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. – a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the commercial availability of Intrarosa™ (prasterone) at pharmacies nationwide, supported by a newly created 137-person women’s health sales... 
From GlobeNewswire News Releases
Daily Technical Summary Reports on Healthcare Stocks -- Valeant Pharma, Palatin Technologies, AMAG Pharma, and IDEXX Labs
From PR Newswire
AMAG Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Thursday, August 3, 2017 at 8:00 a.m. ET
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its second quarter 2017 financial results will be released on Thursday, August 3, 2017 before the U.S. financial markets open. Management... 
From GlobeNewswire News Releases
AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug application (sNDA) for the Makena® subcutaneous... 
From GlobeNewswire News Releases
Stock Performance Review on Healthcare Sector -- Palatin Technologies, Centene, Anthem, and AMAG Pharma
From PR Newswire
AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Velo Bio, LLC has enrolled the first patient in a Phase 2b/3a study designed to evaluate the efficacy and safety of digoxin immune fab... 
From GlobeNewswire News Releases
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: 
From GlobeNewswire News Releases
AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Helen Milton, Ph.D., to the role of vice president of regulatory affairs. Dr. Milton will have responsibility for AMAG’s... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.